247 related articles for article (PubMed ID: 20108024)
1. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.
Suda K; Tomizawa K; Mitsudomi T
Cancer Metastasis Rev; 2010 Mar; 29(1):49-60. PubMed ID: 20108024
[TBL] [Abstract][Full Text] [Related]
2. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
[TBL] [Abstract][Full Text] [Related]
3. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
[TBL] [Abstract][Full Text] [Related]
4. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
[TBL] [Abstract][Full Text] [Related]
5. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
7. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
[TBL] [Abstract][Full Text] [Related]
8. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
Iwakawa R; Kohno T; Anami Y; Noguchi M; Suzuki K; Matsuno Y; Mishima K; Nishikawa R; Tashiro F; Yokota J
Clin Cancer Res; 2008 Jun; 14(12):3746-53. PubMed ID: 18559592
[TBL] [Abstract][Full Text] [Related]
9. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP
Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793
[TBL] [Abstract][Full Text] [Related]
10. EGFR mutations and the terminal respiratory unit.
Yatabe Y
Cancer Metastasis Rev; 2010 Mar; 29(1):23-36. PubMed ID: 20135199
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.
Bonanno L; Schiavon M; Nardo G; Bertorelle R; Bonaldi L; Galligioni A; Indraccolo S; Pasello G; Rea F; Favaretto A
Anticancer Res; 2010 Dec; 30(12):5121-8. PubMed ID: 21187500
[TBL] [Abstract][Full Text] [Related]
12. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor mutations in small cell lung cancer.
Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
[TBL] [Abstract][Full Text] [Related]
14. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
15. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
16. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
17. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML
Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740
[TBL] [Abstract][Full Text] [Related]
18. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Johnson BE; Jänne PA
Cancer Res; 2005 Sep; 65(17):7525-9. PubMed ID: 16140912
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung.
Haneda H; Sasaki H; Shimizu S; Endo K; Suzuki E; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Lung Cancer; 2006 Apr; 52(1):47-52. PubMed ID: 16503085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]